| Literature DB >> 32494145 |
Xuanxuan Jing1, Chen Li1,2, Jintang Sun1, Jin Peng3, Yu Dou4, Xiaofei Xu3, Chao Ma1, Zhaogang Dong5, Yanguo Liu6, Hui Zhang7, Qianqian Shao1, Hui Zhang7, Lijie Wang3, Yun Zhang1, Xun Qu1.
Abstract
PURPOSE: The aim of this study was to find the most useful marker of endometriosis-related infertility and evaluate predictive and diagnostic values of systemic inflammatory response markers (preoperative white blood-cell subtypes, neutrophil:lymphocyte ratio [NLR], platelet:lymphocyte ratio [PLR], and monocyte:lymphocyte ratio [MLR]) and CA125 levels in endometriosis patients.Entities:
Keywords: CA125; NLR; PLR; endometrioma; endometriosis; infertility; uterine leiomyoma
Year: 2020 PMID: 32494145 PMCID: PMC7229864 DOI: 10.2147/TCRM.S232849
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
Figure 1Comparison of NLR and serum CA125 levels in infertie and fertile groups. Mean levels of NLR (A), CA125 (B), and combination of CA125 and NLR (C) in fertile and infertile endometriosis patients.
Univariate Logistic Analysis of Risk Factors of Endometriosis-Associated Infertility
| OR | 95% CI | ||
|---|---|---|---|
| Age (years) | 2.682 | 1.467–4.903 | |
| Unilateral or bilateral cyst | 4.32 | 1.821–10.250 | |
| Diameter of cyst | 6.733 | 3.582–12.653 | |
| Pain | 1.368 | 0.763–2.451 | 0.293 |
| Endometrioma | 1.572 | 0.368–6.727 | 0.542 |
| Uterine leiomyoma | 0.59 | 0.315–1.106 | 0.1 |
| Endometrial polyp | 0.738 | 0.320–1.705 | 0.477 |
| Oviduct adhesion | 4.038 | 1.435–11.362 | |
| Pelvic adhesion | 4.792 | 2.675–8.585 | |
| Clinical stage | 24.843 | 13.007–47.448 | |
| NLR | 0.527 | 0.342–0.814 | |
| CA125 (U/mL) | 0.99 | 0.982–0.997 |
Note: p<0.05 displayed in bold.
Multivariate Logistic Analysis of Risk Factors of Endometriosis-Associated Infertility
| OR | 95% CI | ||
|---|---|---|---|
| Age | 1.925 | 0.904–4.101 | 0.09 |
| Unilateral or bilateral | 2.967 | 1.108–7.944 | |
| Diameter of cyst | 2.656 | 1.185–5.955 | |
| Oviduct adhesion | 1.644 | 0.486–5.554 | 0.424 |
| Pelvic adhesion | 3.648 | 1.773–7.506 | |
| Clinical stage | 8.477 | 3.632–19.785 | |
| NLR | 0.632 | 0.401–0.995 | |
| CA125 (U/mL) | 0.992 | 0.983–1.001 | 0.084 |
Note: p<0.05 displayed in bold.
Figure 2Mean values of NLR, PLR, serum CA125 levels, and combined markers in the two groups. Mean lymphocyte counts (A); serum CA125 (B); NLR (C); MLR (D); PLR (E); combination of NLR and CA125 (F); combination of MLR and CA125 (G); combination of PLR and CA125 (H) in endometriosis group and benign ovarian tumor group.
Figure 3Receiver operating–characteristic curves of NLR, MLR, PLR, CA125, and combined markers. Discrepancy in diagnoses between endometriosis patients and benign-tumor patients assessed using ROC curves. Discrepancy in diagnoses between endometriosis patients and healthy controls assessed using ROC curves.
Diagnostic Sensitivity and Specificity of NLR, MLR, PLR, and CA125 and Combined Markers in Differentiating Endometriosis from Other Benign Ovarian Tumors
| AUC (95% CI) | Sensitivity, % | Specificity, % | Cutoff Value | ||
|---|---|---|---|---|---|
| NLR | 0.56 (0.50–0.62) | 32.90 | 80.20 | 2.26 | |
| MLR | 0.51 (0.45–0.57) | 7.10 | 97.90 | 0.35 | 0.729 |
| PLR | 0.59 (0.54–0.66) | 56.00 | 62.50 | 146.15 | |
| CA125 (U/mL) | 0.86 (0.81–0.91) | 80.60 | 85.40 | 27.03 | |
| NLR–CA125 | 0.85 (0.80–0.90) | 81.30 | 84.40 | 46.42 | |
| PLR–CA125 | 0.86 (0.81–0.91) | 85.10 | 82.30 | 3,477.90 |
Note: p<0.05 displayed in bold.
Figure 4Comparison of endometriosis patients with ovarian endometrioma (OMA), patients with uterine leiomyoma, and controls in terms of WBC subtypes, NLR, MLR, PLR, and CA125. Mean of neutrophil counts (A), monocyte counts (B), lymphocyte counts (C), platelet counts (D), serum CA125 (E), NLR (F), MLR (G), and PLR (H) in endometriosis group, endometriosis patients with uterine leiomyoma, and endometriosis patients with OMA.
Correlations between lymphocyte, NLR, MLR, PLR, and serum CA125 levels and clinicopathological parameters of endometriosis
| n | Lymphocytes (109/L) | NLR | MLR | PLR | CA125 (U/mL) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| <34 | 328 | 1.73±0.48 | 0.495 | 2.39±1.75 | 0.309 | 0.19±0.09 | 0.708 | 274.02±66.08 | 0.169 | 78.25±87.38 | 0.120 |
| ≥34 | 334 | 1.71±0.46 | 2.18±1.46 | 0.19±0.08 | 259.78±61.71 | 74.83±91.89 | |||||
| Unilateral | 446 | 1.72±0.48 | 0.890 | 2.31±1.69 | 0.566 | 0.19±0.09 | 0.370 | 265.11±63.52 | 0.563 | 72.16±90.28 | |
| Bilateral | 216 | 1.72±0.45 | 2.25±1.43 | 0.19±0.09 | 270.39±65.78 | 85.54±87.79 | |||||
| <5 cm | 225 | 1.74±0.49 | 0.430 | 2.09±1.28 | 0.19±0.08 | 0.205 | 266.45±63.31 | 0.664 | 71.40±91.06 | ||
| ≥5 cm | 437 | 1.71±0.46 | 2.38±1.75 | 0.19±0.09 | 267.03±64.82 | 79.16±88.87 | |||||
| No | 188 | 1.72±0.44 | 0.814 | 2.14±1.11 | 0.851 | 0.19±0.08 | 0.626 | 269.94±66.34 | 0.577 | 57.20±59.37 | |
| Yes | 474 | 1.72±0.48 | 2.34±1.77 | 0.20±0.09 | 265.60±63.45 | 84.19±98.11 | |||||
| No | 596 | 1.73±0.47 | 0.475 | 2.30±1.64 | 0.410 | 0.19±0.09 | 0.728 | 267.61±64.83 | 0.884 | 78.33±92.57 | 0.069 |
| Yes | 66 | 1.67±0.45 | 2.13±1.27 | 0.19±0.07 | 259.83±58.90 | 60.22±54.29 | |||||
| No | 512 | 1.72±0.46 | 0.936 | 2.23±1.57 | 0.19±0.08 | 0.384 | 265.07±64.35 | 0.323 | 73.70±89.57 | ||
| Yes | 150 | 1.73±0.51 | 2.47±1.72 | 0.20±0.11 | 272.87±63.82 | 86.16±89.48 | |||||
| No | 208 | 1.69±0.45 | 0.254 | 2.18±1.43 | 0.471 | 0.19±0.08 | 0.130 | 260.21±67.25 | 0.325 | 72.47±95.59 | 0.088 |
| Yes | 454 | 1.73±0.48 | 2.33±1.68 | 0.19±0.09 | 269.87±62.69 | 78.38±86.81 | |||||
| Stages I–II | 61 | 1.80±0.49 | 0.752 | 1.95±1.12 | 0.18±0.07 | 0.166 | 161.13±65.28 | 0.260 | 17.28±5.02 | ||
| Stages III–V | 601 | 1.72±0.47 | 2.37±1.69 | 0.19±0.09 | 166.11±59.04 | 82.71±92.06 |
Notes: Student's t-test used. p<0.05 are displayed in bold.